(Q45002890)

8 December 2017

0 references

Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation (English)

1 reference

8 December 2017

1 reference

Angelina Daisy Goodrich

series ordinal

1

object named as

Angelina Daisy Goodrich

0 references

publication date

9 September 2014

1 reference

Expert Review of Hematology

8 December 2017

1 reference

8 December 2017

7

1 reference

8 December 2017

5

1 reference

8 December 2017

513-515

1 reference

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics

8 December 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.958465

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.958465

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.958465

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.958465

Ponatinib in refractory Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.958465

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.958465

A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.958465

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.958465

10.1586/17474086.2014.958465

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference

PubMed ID

25199408